CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS/STING pathway. (PubMed, Cancer Lett) - Sep 20, 2026 - "Moreover, the combination of mitotic kinase inhibitors and the microtubules-targeting agent vincristine (VCR) exhibit synergistic anti-tumor effects in B-cell lymphoma mouse models...To enhance targeting specificity toward CD20+ lymphoma cells, rituximab (RTX) was conjugated onto the nanomedicine, named VCR/[email protected], VCR/siPLK4@ZIF-90-RTX could promote the maturation of dendritic cells and subsequent tumor infiltration of CD8+ T and CD4+ T cells by activating cGAS-STING pathway. Collectively, this work provides a potential synergistic chemo-immunotherapeutic strategy that effectively remodels the immunosuppressive TME and improves therapeutic efficacy."
IO biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD20 • CD4 • CD8 • PLK4
|
|
Bin Zhang; Cen Meng; Chunyang Tian; Jiayuan Chen; Nannan Xu; Ruowen Sun; Ye Wang; Ying Sun; Zehui Jiang; Zuofei Chi
|